El interés en corto de Korro Bio da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Korro Bio. Los datos de interés en corto se actualizan cada dos semanas.

Korro Bio (NASDAQ:KRRO) Bolsa, Informe de interés en corto

Korro Bio

Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.

Korro Bio Inc

News

SMCI

Supermicro Announces Plans For Third Silicon Valley Campus

Management

BMBL

Bumble Appoints Ronald J. Fior Appointed Interim CFO, Effective March 15, 2025

<p><a href="https://www.bloomberg.com/news/articles/2025-02-28/synopsys-preparing-around-10-billion-bond-deal-for-next-week?srnd=homepage-americas" title="https://www.bloomberg.com/news/articles/2025-02-28/synopsys-preparing-around-10-billion-bond-deal-for-next-week?srnd=homepage-americas">https://www.bloomberg.com/news/articles/2025-02-28/synopsys-preparing-around-10-billion-bond-deal-for-next-week?srnd=homepage-americas</a></p>


SNPS

'Synopsys Preparing Around $10B Bond Deal for Next Week' - Bloomberg News

<p>Apogee Therapeutics, Inc., (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APGE#NASDAQ">APGE</a>), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&amp;I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD) and other I&amp;I indications, today announced it will report interim results from the Phase 1 APG990 healthy volunteer trial on Monday, March 3, 2025. Following the announcement, the Company will host a conference call and webcast at 8:30am ET to discuss the results and plans for its combination approach for APG777 + APG990.</p>
<p><strong>Webcast Details</strong><br /><br />Apogee Therapeutics' live webcast of the APG990 interim Phase 1 results will begin on Monday, March 3rd at 8:30 a.m. ET. The live webcast can be accessed via this <a href="https://www.globenewswire.com/Tracker?data=xTTBB-uG28xqNOQCwuu2d3nWIGl2LT_1OcbR38xc95J0Wh1lSIdaaZLfjt-FYrAHOCKBMVtj73mUCabW265I13PcZKaZAsld7gX2LKxdvZY=">link</a> or the Investors section on the Company's website at <a href="https://www.globenewswire.com/Tracker?data=PD39gvBcZGVl3b2QDsK11co25GljqTknDn07vv3oxkfitQEOakYxn2-HbWuaeuI5mtPQQlKbOBcQ2DchxXY7b_8YwFE5Wzz9gudKd0qq15ht6Tqi5nOFEyeBJMNd1kfSKUEO-Ka5cLRuMeNRrMJbWNTNuGNotsb6eTLp84H_7kvE2hwbOfGhudHD1mht5p8X">https://investors.apogeetherapeutics.com/news-events/events</a>. A replay of the webcast will be available following the call.</p>


Biotech

General

APGE

Apogee Therapeutics To Host Conference Call To Report Interim Results From The Phase 1 Healthy Volunteer Trial For APG990 And Provide Combination Strategy Update On March 3, 2025 At 8:30am ET

<p>Risk assets tumbled as a wave of bearish sentiment gripped markets, with escalating trade tensions, disappointing earnings and signs of economic fragility weighing on investor confidence.</p>
<p>President Donald Trump confirmed <a href="https://www.benzinga.com/news/global/25/02/43926015/trump-confirms-tariffs-on-canada-mexico-will-take-effect-as-planned">a 25% tariff on imports from Mexico and Canada</a>, effective March 4, while also targeting European Union's goods including automobiles and imposing an additional 10% tariff on Chinese imports.&nbsp;</p>
<p>The sweeping trade measures rattled markets, triggering broad-based sell-offs, with cryptocurrencies bearing the brunt of risk aversion.&nbsp;</p>
<p>Though seeing a small uptick after it plunged below $80,000 in early Friday trading, <strong>Bitcoin </strong>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) is still entering a bear market after dropping more <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43987636/bitcoin-tumbles-below-85000-amid-president-trumps-eu-tariff-threats">than 20% from its peak.</a> Sentiment in the digital asset space worsened following a massive security breach at Bybit, where hackers stole $1.5 billion worth of<strong> Ethereum </strong>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) in one of the largest <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43942256/making-ethereum-private-again-a-1-5-billion-wake-up-call">crypto heists in history.</a></p>
<p>The high-flying artificial intelligence sector took a hit as investors <a href="https://www.benzinga.com/25/02/44034855/this-is-as-good-as-it-gets-for-nvidia-says-this-analyst-as-he-predicts-a-slowdown-for-the-chipmaker">reassessed its lofty valuations</a>. <strong>NVIDIA Corp.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) suffered steep losses after delivering earnings that, while stronger-than-expected, failed to astonish investors accustomed to impressive beats. The stock's sharp retreat dragged down peers Advanced Micro Devices Inc., Broadcom Inc., Qualcomm Inc. and Intel Corp., all of which saw declines.</p>
<p>Fresh cracks in economic data emerged, adding to investor anxiety. While the fourth-quarter <a href="https://www.benzinga.com/news/econ-s/25/02/44007082/q4-gdp-holds-at-2-3-after-minor-revision-in-second-estimate">gross domestic product remained unchanged</a> at an annualized 2.3% growth rate, inflation metrics for the same quarter were revised higher.</p>
<p>In January, personal spending contracted by 0.2% on the month, marking the first negative reading since March 2023. The Personal Consumption Expenditure price index — Fed's favorite inflation gauge — came in at 2.5% as expected, remaining above the 2% target.&nbsp;</p>
<p>Housing data also disappointed, with pending home sales plunging 4.6% in January to their lowest level on record. Elevated mortgage rates continued to strain affordability, further cooling demand <a href="https://www.benzinga.com/general/market-summary/25/02/44015237/pending-home-sales-crash-to-record-low-jobless-claims-soar-wall-street-reacts">in the housing market</a>.</p>
<p>The labor market showed signs of softening, as weekly jobless claims jumped by 22,000 to 242,000, marking the highest level in over two months.</p>
<p><strong>GM Boosts Dividends</strong></p>
<p><strong>General Motors Co. </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) rewarded shareholders with a dividend hike and a fresh buyback plan. The automaker raised its quarterly dividend by three cents to 15 cents per share, effective with its next payout in April. GM also authorized a new $6 billion share repurchase program, including a $2 <a href="https://www.benzinga.com/trading-ideas/movers/25/02/43976235/why-general-motors-stock-is-gaining-today">billion accelerated buyback initiative</a>.</p>
<p><strong>Read Next: <br />    •<a href="https://www.benzinga.com/news/econ-s/25/02/44055933/investor-bearishness-surges-yet-historical-data-suggests-potential-market-gains-ahead"> Investor Bearishness Surges, Yet Historical Data Suggests Potential Market Gains Ahead</a></strong></p>
<p><em>Photo: Shutterstock</em></p>


Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Federal Reserve

Tech

Trading Ideas

$BTC

$ETH

NVDA

Tariffs Shock Hit Stocks, Cryptos, While Nvidia Fails To Come To The Rescue: This Week In Markets

<p>In the last three months, 5 analysts have published ratings on SoundHound AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for SoundHound AI, revealing an average target of $19.0, a high estimate of $26.00, and a low estimate of $8.00. Observing a 59.66% increase, the current average has risen from the previous average price target of $11.90. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740776473_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>A clear picture of SoundHound AI's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$13.00</td>
<td>$9.50</td>
</tr>
<tr>
<td>Michael Latimore</td>
<td>Northland Capital Markets</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$8.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>Scott Buck</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$26.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Scott Buck</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$26.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$22.00</td>
<td>$10.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to SoundHound AI. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of SoundHound AI compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for SoundHound AI's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of SoundHound AI's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/SOUN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on SoundHound AI analyst ratings.</strong></a></p>
<h2>Delving into SoundHound AI's Background</h2>
<p>SoundHound AI Inc is an innovator of conversational intelligence, offering an independent Voice AI platform that enables businesses across industries to deliver high-quality conversational experiences to customers.</p>
<h3>SoundHound AI: Financial Performance Dissected</h3>
<p><strong>Market Capitalization:</strong> Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.</p>
<p><strong>Revenue Growth:</strong> SoundHound AI's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of <strong>89.13%</strong>. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Information Technology sector.</p>
<p><strong>Net Margin:</strong> SoundHound AI's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>-86.68%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> SoundHound AI's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-8.37%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-5.68%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.15</strong>.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

SOUN

Beyond The Numbers: 5 Analysts Discuss SoundHound AI Stock

<p>Throughout the last three months, 5 analysts have evaluated Standex International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SXI#NYSE">SXI</a>), offering a diverse set of opinions from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $220.8, with a high estimate of $224.00 and a low estimate of $220.00. This current average has increased by 0.18% from the previous average price target of $220.40. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740776462_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>The standing of Standex International among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gary Prestopino</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$220.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Michael Shlisky</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$224.00</td>
<td>$222.00</td>
</tr>
<tr>
<td>Gary Prestopino</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$220.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Gary Prestopino</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$220.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Gary Prestopino</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$220.00</td>
<td>$220.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Standex International. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Standex International compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Standex International's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Standex International's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/SXI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Standex International analyst ratings.</strong></a></p>
<h2>Get to Know Standex International Better</h2>
<p>Standex International Corp is an industrial manufacturer of different products and services used in commercial and industrial markets. It has five reportable segments; Electronics; Engraving; Scientific; Engineering Technologies and Specialty Solutions. The maximum revenue is generated from its Electronics segment which is a component and value-added services provider of both sensing and switching technologies as well as magnetic power conversion components and assemblies, like custom wound transformers and inductors, current sense technology, value-added assemblies, and mechanical packaging among others. Geographically, it derives key revenue from the United States and the rest from Asia Pacific, Europe, Middle East and South Africa (EMEA), and other regions.</p>
<h3>Standex International: Delving into Financials</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Standex International's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately <strong>6.4%</strong>. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> Standex International's net margin is impressive, surpassing industry averages. With a net margin of <strong>0.45%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>0.13%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>0.07%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Standex International's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>0.88</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


5 Analysts Assess Standex International: What You Need To Know

<p>Ratings for Kontoor Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KTB#NYSE">KTB</a>) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $99.25, with a high estimate of $108.00 and a low estimate of $93.00. A decline of 4.34% from the prior average price target is evident in the current average. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740776454_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>A comprehensive examination of how financial experts perceive Kontoor Brands is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jay Sole</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$96.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Paul Kearney</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$93.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$100.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Jay Sole</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$108.00</td>
<td>$112.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Kontoor Brands. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Kontoor Brands compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Kontoor Brands's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Kontoor Brands's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/KTB/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Kontoor Brands analyst ratings.</strong></a></p>
<h2>Delving into Kontoor Brands's Background</h2>
<p>Kontoor Brands Inc is a lifestyle apparel company. It is engaged in designing, manufacturing, sourcing, marketing, and distribution of its portfolio of brands, including Wrangler and Lee. It manufactures its products in owned and leased facilities and distributes the products through both brick-and-mortar and e-commerce retailers. The Company has two reportable segments: Wrangler and Lee. It generates the majority of its revenue from the Wrangler segment. The company's geographical segments are the United States and International, of which the majority of its revenue comes from the United States.</p>
<h3>Kontoor Brands: Delving into Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Kontoor Brands's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of <strong>4.4%</strong>. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>9.15%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Kontoor Brands's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>16.9%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Kontoor Brands's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>3.87%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>1.98</strong>, Kontoor Brands adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


What Analysts Are Saying About Kontoor Brands Stock

<p>Ratings for Golden Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDEN#NASDAQ">GDEN</a>) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Golden Entertainment, presenting an average target of $36.6, a high estimate of $40.00, and a low estimate of $32.00. This current average reflects an increase of 2.38% from the previous average price target of $35.75. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740776447_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Golden Entertainment. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jordan Bender</td>
<td>Citizens Capital Markets</td>
<td>Raises</td>
<td>Outperform</td>
<td>$37.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Chad Beynon</td>
<td>Macquarie</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Jordan Bender</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$36.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Cassandra Lee</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$32.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Zachary Silverberg</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Overweight</td>
<td>$38.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Golden Entertainment. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Golden Entertainment compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Golden Entertainment's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Golden Entertainment's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/GDEN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Golden Entertainment analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>Discovering Golden Entertainment: A Closer Look</h2>
<p>Golden Entertainment Inc is a U.S. based company that focuses on distributed gaming, casino, and resort operations. Its reportable segments are Nevada Casino Resorts, Nevada Locals Casinos, Nevada Taverns, and Distributed Gaming. The majority of the revenue for the company is generated from its Nevada Casino Resorts segment which is comprised of destination casino resort properties offering a variety of food and beverage outlets, entertainment venues, and other amenities.</p>
<h3>Unraveling the Financial Story of Golden Entertainment</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Golden Entertainment's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately <strong>-37.44%</strong> in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> Golden Entertainment's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>3.2%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Golden Entertainment's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>0.98%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Golden Entertainment's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>0.45%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> Golden Entertainment's debt-to-equity ratio is below the industry average. With a ratio of <b>0.95</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


GDEN

Beyond The Numbers: 5 Analysts Discuss Golden Entertainment Stock

VINC

Trading Halt: Halted at 4:00:10 p.m. ET - Trading Halt: Halt News Pending

SYRS

<p>6 analysts have expressed a variety of opinions on Aris Water Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARIS#NYSE">ARIS</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Aris Water Solutions and provided 12-month price targets. The average target is $27.67, accompanied by a high estimate of $30.00 and a low estimate of $26.00. This current average has increased by 21.2% from the previous average price target of $22.83. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740776428_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>The perception of Aris Water Solutions by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Praneeth Satish</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$29.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Samantha Hoh</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$27.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Spiro Dounis</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$26.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>John Mackay</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$30.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Praneeth Satish</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$26.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Selman Akyol</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$28.00</td>
<td>$26.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Aris Water Solutions. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Aris Water Solutions compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Aris Water Solutions's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Aris Water Solutions's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ARIS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Aris Water Solutions analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>Discovering Aris Water Solutions: A Closer Look</h2>
<p>Aris Water Solutions Inc is an environmental infrastructure and solutions company that helps customers reduce their water and carbon footprints. It has two primary revenue streams. The Produced Water Handling business gathers, transports, and, unless recycled, handles produced water generated from oil and natural gas production. The Water Solutions business develops and operates recycling facilities to treat, store and recycle produced water.</p>
<h3>A Deep Dive into Aris Water Solutions's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Aris Water Solutions's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>12.55%</strong> as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Energy sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>6.67%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Aris Water Solutions's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>2.21%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Aris Water Solutions's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>0.54%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>1.37</strong>, Aris Water Solutions adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


ARIS

6 Analysts Have This To Say About Aris Water Solutions

<p>ConocoPhillips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COP#NYSE">COP</a>) has outperformed the market over the past 5 years by 1.01% on an annualized basis producing an average annual return of 15.47%. Currently, ConocoPhillips has a market capitalization of $124.25 billion. </p>
<p><strong>Buying $1000 In COP:</strong> If an investor had bought $1000 of COP stock 5 years ago, it would be worth <strong>$2,006.09</strong> today based on a price of $97.65 for COP at the time of writing.</p>
<h3>ConocoPhillips's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740776425_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Here's How Much $1000 Invested In ConocoPhillips 5 Years Ago Would Be Worth Today

<p>4 analysts have shared their evaluations of Universal Health Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $227.0, a high estimate of $249.00, and a low estimate of $210.00. This current average has decreased by 1.45% from the previous average price target of $230.33. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740776419_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>A comprehensive examination of how financial experts perceive Universal Health Servs is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scott Fidel</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$223.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Raj Kumar</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$210.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$249.00</td>
<td>$271.00</td>
</tr>
<tr>
<td>Benjamin Rossi</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Neutral</td>
<td>$226.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Universal Health Servs. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Universal Health Servs compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Universal Health Servs's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Universal Health Servs's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/UHS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Universal Health Servs analyst ratings.</strong></a></p>
<h2>Discovering Universal Health Servs: A Closer Look</h2>
<p>Universal Health Services Inc owns and operates acute care hospitals, behavior health centers, surgical hospitals, ambulatory surgery centers, and radiation oncology centers. The firm operates in two key segments: Acute Care Hospital Services and Behavioral Health Services. The Acute Care Hospital Services segment includes the firm's acute care hospitals, surgical hospitals, and surgery and oncology centers.</p>
<h3>Universal Health Servs: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Universal Health Servs showcased positive performance, achieving a revenue growth rate of <strong>11.08%</strong> as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Universal Health Servs's net margin is impressive, surpassing industry averages. With a net margin of <strong>8.08%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>5.01%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>2.31%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Universal Health Servs's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.74</strong>.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Where Universal Health Servs Stands With Analysts

WIIM

Booz Allen Hamilton shares are trading lower following a WSJ report suggesting the company is exposed to government budget cuts.

ENSG

UHAL

Shares of hospital an healthcare stocks are trading lower amid concerns over Medicaid an Medicare cuts. Additionally, President Trump recently signed an executive order on healthcare price transparency.

PSTV

Plus Therapeutics shares are trading higher after the company was granted FDA Orphan Drug Designation for BMEDA-Chelated Rhenium-186 Nanoliposomes for the treatment of lung cancer with leptomeningeal metastases.

<p><a href="https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=969223" title="https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=969223">https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=969223</a></p>


Plus Therapeutics Granted FDA Orphan Designation For BMEDA-Chelated Rhenium-186 Nanoliposomes For The Treatment Of Lung Cancer With Leptomeningeal Metastases

<p>Energy markets popped Friday afternoon after a <a href="https://www.benzinga.com/news/global/25/02/44053592/white-house-meeting-turns-tense-as-trump-warns-zelenskyy-youre-gambling-with-world-war-iii">heated exchange</a> between former <strong>President Donald Trump</strong>, <strong>Vice President JD Vance</strong> and <strong>Ukrainian President Volodymyr Zelenskyy</strong> at the White House. </p>
<p>The diplomatic clash, which centered on U.S. military aid to Ukraine and broader foreign policy tensions, could fuel investor concerns over geopolitical stability, sending energy-related assets higher.</p>
<p><strong>What To Know:</strong> The <strong>Energy Select Sector SPDR Fund</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NASDAQ">XLE</a>), which tracks major U.S. energy companies, and the <strong>United States Oil Fund LP</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USO#NASDAQ">USO</a>), which follows <strong>West Texas Intermediate</strong> crude oil prices, both saw volatility amid rising uncertainty in global energy markets.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/general/market-summary/25/02/44051518/nvidia-tesla-lead-tech-stock-rebound-whats-driving-markets-friday">Nvidia, Tesla Lead Tech Stock Rebound: What&#8217;s Driving Markets Friday?</a></strong></p>
<p>The friction between U.S. and Ukrainian leadership may signal a potential shift in American foreign policy, particularly regarding its support for Ukraine. Trump and Vance&#8217;s skepticism toward continued military aid raises concerns that a reduction in assistance could embolden Russia, potentially escalating the ongoing war. </p>
<p>The prospect of prolonged or intensified conflict in Eastern Europe often leads to a surge in crude prices, benefiting funds like USO. Simultaneously, rising oil prices boost the profitability of U.S. energy companies, lifting stocks within XLE.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/25/02/44049626/key-inflation-measure-falls-in-january-should-catch-the-feds-attention-expert-says">Key Inflation Measure Falls In January: &#8216;Should Catch The Fed&#8217;s Attention,&#8217; Economist Says</a></strong></p>


Energy Markets Volatile As Trump, Vance Clash with Zelenskyy Over Ukraine Aid

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>Lemonade</strong>.</p>
<p>Looking at options history for Lemonade (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMND#NYSE">LMND</a>) we detected 12 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 50% of the investors opened trades with bullish expectations and 50% with bearish.</p>
<p>From the overall spotted trades, 5 are puts, for a total amount of $233,560 and 7, calls, for a total amount of $350,204.</p>
<h3>Expected Price Movements</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $17.0 and $50.0 for Lemonade, spanning the last three months.</p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Lemonade's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Lemonade's whale trades within a strike price range from $17.0 to $50.0 in the last 30 days. </p>
<h3>Lemonade Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740775617_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>LMND</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/28/25</td>
<td>$9.6</td>
<td>$8.3</td>
<td>$8.45</td>
<td>$28.00</td>
<td>$168.1K</td>
<td align="right">201</td>
<td align="right">201</td>
</tr>
<tr>
<td>LMND</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/14/25</td>
<td>$3.2</td>
<td>$3.1</td>
<td>$3.11</td>
<td>$36.00</td>
<td>$62.2K</td>
<td align="right">25</td>
<td align="right">605</td>
</tr>
<tr>
<td>LMND</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/28/25</td>
<td>$3.6</td>
<td>$3.5</td>
<td>$3.5</td>
<td>$35.00</td>
<td>$54.2K</td>
<td align="right">72</td>
<td align="right">164</td>
</tr>
<tr>
<td>LMND</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/14/25</td>
<td>$2.6</td>
<td>$2.5</td>
<td>$2.6</td>
<td>$35.00</td>
<td>$51.9K</td>
<td align="right">147</td>
<td align="right">355</td>
</tr>
<tr>
<td>LMND</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$16.5</td>
<td>$16.3</td>
<td>$16.5</td>
<td>$45.00</td>
<td>$39.6K</td>
<td align="right">7</td>
<td align="right">25</td>
</tr>
</tbody>
</table>
</p>
<h3>About Lemonade</h3>
<p>Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes. The company is using technology, data, artificial intelligence, contemporary design, and social impact to deliver delightful and affordable insurances. Geographically, it operates in California, Texas, New York, New Jersey, Illinois, Georgia, Washington, Colorado, Pennsylvania, Oregon and others.</p>
<p>In light of the recent options history for Lemonade, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Present Market Standing of Lemonade</h3>
<ul>
<li>With a volume of 1,905,991, the price of LMND is down -3.95% at $34.06. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 60 days.</li>
</ul>
<h3>What Analysts Are Saying About Lemonade</h3>
<p>2 market experts have recently issued ratings for this stock, with a consensus target price of $47.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Piper Sandler has decided to maintain their Neutral rating on Lemonade, which currently sits at a price target of $34.<br />
&#x2A; In a cautious move, an analyst from Citizens Capital Markets downgraded its rating to Market Outperform, setting a price target of $60. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Lemonade, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

Markets

LMND

A Closer Look at Lemonade's Options Market Dynamics

Press Releases

Korro Announces Oral and Poster Presentations at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society

Korro Announces Regulatory Filing for Initiation of KRRO-110 First-In-Human Study and Formation of Clinical Advisory Board

Earnings

Korro Reports Third Quarter 2024 Financial Results and Provides Business Updates

Korro to Present at the Jefferies London Healthcare Conference

Health Care

Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO-110 for Alpha-1 Antitrypsin Deficiency

Korro to Participate in Upcoming Investor Conferences

CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors

Korro to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Korro Bio Announces Dosing of First Participants in REWRITE Phase 1/2a Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency and Provides Pipeline Update

Korro to Present at the TD Cowen 45th Annual Health Care Conference

CAMP

KRRO

Abeona Therapeutics

Amarin Corporation plc - American Depositary Shares, each representing one Ordinary Share

Comments

Korro Bio

Interés en corto

Korro Bio (NASDAQ:KRRO) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL